OBJECTIVE: To determine which glucose levels are associated with improved morbidity and mortality in thermally injured patients. SUMMARY BACKGROUND DATA: Tight euglycemic control was rapidly implemented in intensive care units around the world, but there is increasing evidence that tight euglycemic control is associated with detrimental outcomes. Currently, no study exists that indicates which glucose range should be targeted. METHODS:Two-hundred and eight severely burned pediatric patients with burns over 30% of their total body surface area were included in this trial. Several statistical models were used to determine the daily average and 6 AM glucose target that were associated with improved morbidity and mortality. Patients were then divided into good glucose controlled and poor glucose controlled patients and demographics, clinical outcomes, infection, sepsis, inflammatory, and hypermetabolic responses were determined. RESULTS: Statistical modeling showed that hyperglycemia is a strong predictor of adverse hospital outcome and that daily 6 am glucose level of 130 mg/dL and daily average glucose levels of 140 mg/dL are associated with improved morbidity and mortality postburn. When patients were divided into good glucose control and poor glucose control, we found that patients with glucose levels of 130 mg/dL exert attenuated hypermetabolic and inflammatory responses, as well as significantly lower incidence of infections, sepsis, and mortality compared with patients with poor glucose control, P < 0.05. CONCLUSIONS: Given the controversy over glucose range, glucose target, and risks and detrimental outcomes associated with hypoglycemia we suggest that in severely burned patient's blood glucose of 130 mg/dL should be targeted.
RCT Entities:
OBJECTIVE: To determine which glucose levels are associated with improved morbidity and mortality in thermally injured patients. SUMMARY BACKGROUND DATA: Tight euglycemic control was rapidly implemented in intensive care units around the world, but there is increasing evidence that tight euglycemic control is associated with detrimental outcomes. Currently, no study exists that indicates which glucose range should be targeted. METHODS: Two-hundred and eight severely burned pediatricpatients with burns over 30% of their total body surface area were included in this trial. Several statistical models were used to determine the daily average and 6 AM glucose target that were associated with improved morbidity and mortality. Patients were then divided into good glucose controlled and poor glucose controlled patients and demographics, clinical outcomes, infection, sepsis, inflammatory, and hypermetabolic responses were determined. RESULTS: Statistical modeling showed that hyperglycemia is a strong predictor of adverse hospital outcome and that daily 6 am glucose level of 130 mg/dL and daily average glucose levels of 140 mg/dL are associated with improved morbidity and mortality postburn. When patients were divided into good glucose control and poor glucose control, we found that patients with glucose levels of 130 mg/dL exert attenuated hypermetabolic and inflammatory responses, as well as significantly lower incidence of infections, sepsis, and mortality compared with patients with poor glucose control, P < 0.05. CONCLUSIONS: Given the controversy over glucose range, glucose target, and risks and detrimental outcomes associated with hypoglycemia we suggest that in severely burned patient's blood glucose of 130 mg/dL should be targeted.
Authors: G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: D W Hart; S E Wolf; D L Chinkes; D C Gore; R P Mlcak; R B Beauford; M K Obeng; S Lal; W F Gold; R R Wolfe; D N Herndon Journal: Ann Surg Date: 2000-10 Impact factor: 12.969
Authors: Marc G Jeschke; Gerd G Gauglitz; Juquan Song; Gabriela A Kulp; Celeste C Finnerty; Robert A Cox; José M Barral; David N Herndon; Darren Boehning Journal: J Cell Mol Med Date: 2009-08 Impact factor: 5.310
Authors: D W Hart; S E Wolf; R Mlcak; D L Chinkes; P I Ramzy; M K Obeng; A A Ferrando; R R Wolfe; D N Herndon Journal: Surgery Date: 2000-08 Impact factor: 3.982
Authors: Dennis C Gore; David L Chinkes; David W Hart; Steven E Wolf; David N Herndon; Arthur P Sanford Journal: Crit Care Med Date: 2002-11 Impact factor: 7.598
Authors: Celeste C Finnerty; Arham Ali; Josef McLean; Nicole Benjamin; Robert P Clayton; Clark R Andersen; Ronald P Mlcak; Oscar E Suman; Walter Meyer; David N Herndon Journal: J Am Coll Surg Date: 2014-01-24 Impact factor: 6.113
Authors: Eliotte L Hirshberg; Michael J Lanspa; Emily L Wilson; Katherine A Sward; Al Jephson; Gitte Y Larsen; Alan H Morris Journal: Diabetes Technol Ther Date: 2017-03-01 Impact factor: 6.118
Authors: Robert Kraft; David N Herndon; Celeste C Finnerty; Yaeko Hiyama; Marc G Jeschke Journal: J Clin Endocrinol Metab Date: 2012-11-12 Impact factor: 5.958